文献速递角膜与眼表疾病

胸腺素β4通过抑制Th17细胞反应减轻自身免疫性泪腺炎

Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

本研究在兔自身免疫性泪腺炎(干燥综合征干眼动物模型)中局部给予重组胸腺素β4(rTβ4)或PBS治疗28天,发现rTβ4可改善眼表炎症和临床症状,抑制泪腺中Th17相关基因及IL-17表达,机制可能部分通过抑制STAT3磷酸化实现。

要点

  • 局部rTβ4可减轻兔自身免疫性泪腺炎的眼表炎症和临床症状。
  • rTβ4抑制泪腺Th17相关基因(RORC、IL-17A、IL-17F等)及IL-17蛋白表达。
  • rTβ4在体内外抑制STAT3磷酸化,Colivelin激活STAT3可部分逆转其抑制IL-17的效果。

核心结论

  • rTβ4可减轻兔正在进行的自身免疫性泪腺炎,可能通过部分影响STAT3通路抑制Th17反应。
  • 这些数据可能为rTβ4在干燥综合征相关干眼中的治疗作用和机制提供新见解。

研究设计与样本

  • 研究为兔自身免疫性泪腺炎动物模型实验,疾病发作后局部给予rTβ4或PBS溶液治疗28天。
  • 通过评估泪液分泌、泪膜破裂时间、荧光素染色、苏木精-伊红染色和过碘酸-雪夫染色确定临床评分。

主要发现

  • 疾病发作后局部给予rTβ4有效改善眼表炎症并缓解临床症状。
  • rTβ4治疗显著抑制泪腺中Th17相关基因(RORC、IL-17A、IL-17F、IL-1R1、IL-23R和粒细胞-巨噬细胞集落刺激因子)及IL-17蛋白表达,同时降低炎症介质表达。
  • rTβ4在体内和体外均抑制信号转导与转录激活因子3(STAT3)的磷酸化。
  • 体外实验中,Colivelin激活STAT3信号通路部分逆转了rTβ4对IL-17表达的抑制作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the therapeutic effect of recombinant thymosin β4 (rTβ4) on rabbit autoimmune dacryoadenitis, an animal model of SS dry eye, and explore its mechanisms. METHODS: Rabbits were treated topically with rTβ4 or PBS solution after disease onset for 28 days, and clinical scores were determined by assessing tear secretion, break-up time, fluorescein, hematoxylin and eosin staining, and periodic acid-Schiff. The expression of inflammatory mediators in the lacrimal glands were measured by real-time PCR. The expression of T helper 17 (Th17) cell-related transcription factors and cytokines were detected by real-time PCR and Western blotting. The molecular mechanism underlying the effects of rTβ4 on Th17 cell responses was investigated by Western blotting. RESULTS: Topical administration of rTβ4 after disease onset efficiently ameliorated the ocular surface inflammation and relieved the clinical symptoms. Further analysis revealed that rTβ4 treatment significantly inhibited the expression of Th17-related genes (RORC, IL-17A, IL-17F, IL-1R1, IL-23R, and granulocyte-macrophage colony-stimulating factor) and IL-17 protein in lacrimal glands, and meanwhile decreased the inflammatory mediators expression. Mechanistically, we demonstrated that rTβ4 repressed the phosphorylation of signal transducer and activator of transcription 3 (STAT3) both in vivo and in vitro. Activation of the STAT3 signal pathway by Colivelin partly reversed the suppressive effects of rTβ4 on IL-17 expression in vitro. CONCLUSIONS: rTβ4 could alleviate ongoing autoimmune dacryoadenitis in rabbits, probably by suppressing Th17 response via partly affecting the STAT3 pathway. These data may provide a new insight into the therapeutic effect and mechanism of rTβ4 in dry eye associated with Sjögren's syndrome.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhao X, Li N, Yang N, et al. Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response. Invest Ophthalmol Vis Sci. 2023. PMID: 37531112. doi:10.1167/iovs.64.11.3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。